Phaseline

Companies › YolTech Therapeutics

YolTech Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Genitourinary; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YOLT-203
Gene editing therapy for alanine-glyoxylate aminotransferase (AGXT) deficiency
AGXTPhase 2Primary Hyperoxaluria Type 1Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07587021YOLT-203Phase 2Primary Hyperoxaluria Type 1GenitourinaryAug 2027
NCT07776626YOLT-203Phase 1Primary Hyperoxaluria Type 1GenitourinaryOct 2027

Targets

AGXT (1)

Companies with the same targets

Arbor Biotechnologies

Companies built like this

Cisen Pharmaceutical Levee Medical Vensica Therapeutics Urotronic Prokidney

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.